A new treatment called a “living drug” modifies immune cells of the patient and ‘teaches’ them to attack cancer cells. The drug known as CAR-T cell immunotherapy was approved by FDA to be used for children and young adults with ...

The drug, larotrectinib, directly targets an acquired rather than inherited genetic defect called TRK fusions. In such patients, TRK genes abnormally attach to other genes, triggering accelerated cancer cell growth, according to Reuters. If approved, the oral therapy would mark a ...

Kite Pharma, a US pharmaceutical company, just released the groundbreaking results of their six-month gene therapy trial: terminal cancer patients in complete remission after just a single round, Joinfo.com reports with reference to Futurism. The treatment filters a patient’s blood ...